Media & Investor Relations

Resources and materials for investors and media

InSitu Biologics

InSitu Biologics, LLC is an emerging drug delivery company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.

For Media & Press

Please contact

Katie M.
Katie@insitubiologics.com

For Investors

Please contact

Jim Segermark, CEO
Jim@insitubiologics.com
651-337-4799

Pre-Clinical Results

As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.

300% Longer

Initial animal study revealed AnestaGel™ lasted up to 300% longer

8x More Capacity

AnestaGel™ carried 8 times more payload

72+ Hours

AnestaGel™ had full nerve block beyond 72 hours

Investment Opportunity

InSitu Biologics intends to launch a Regulation A+ offering to a limited number of investors.

Why Invest

  • 22+ US Patents Issued, with matching OUS positions
  • Hydrogel technology licensed from Cleveland Clinic Foundation
  • Tunable, biocompatible, and pH neutral platform
  • High dose drug-load reservoir capacity with a predictable pharmacological effect
  • Non-opioid pain relief option
  • Early-stage venture opportunity

The Offering

Pre-Valuation
$24,035,753
Max Raise
$10,000,009.50
Min. Per Investor
$287.50
Price Per Share
$5.75

Competitor Market Size

Timeline

  • 2015

    Q1
    Defined the Matrix and AnestaGel

    Q2
    Raised $1 million

    Q3
    Completed first pre-clinical study

    Q4
    Analysis showed statistical success compared to Exparel

  • 2016

    Q1
    Filed additional patent(s)

    Q2
    White Paper published

    Q3
    Completed maximum dosing study with no toxicity

    Q4
    Presented at PODD-Boston

  • 2017

    Q1
    Completed first GLP study

    Q2
    Proved more pain relief compared to Exparel in pre-clinical study

    Q3
    GLP publication accepted

    Q4
    Raised over $400k

  • 2018

    Q1
    Completed Financial Audit
    Converted all debt
    Filed $10,000,000 RegA+ Offering

    Q2
    Launch RegA+ Offering
    Announce GLP Paper by Hutchins & Taylor

    Q3
    Announce final GLP Study results
    Begin Phase 1 manufacturing

    Q4
    Expect approval for Phase 1 Clinical Study of AnestaGel

Team

James Segermark

CEO

Bill Taylor

Chief Scientist

Daniel Sipple

DO Medical Advisor

Jacob Hutchins

MD Medical Advisor

Get in Touch

For media or investor inquires please contact
Contact Us